# NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

> **NCT04539808** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 42 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8
- Stage I Pancreatic Cancer American Joint Committee on Cancer v8
- Stage III Pancreatic Cancer American Joint Committee on Cancer v8
- Stage IV Pancreatic Cancer American Joint Committee on Cancer v8

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Leucovorin Calcium
- **DRUG:** Losartan Potassium
- **DRUG:** Oxaliplatin
- **RADIATION:** Radiation Therapy
- **PROCEDURE:** Resection
- **PROCEDURE:** Diagnostic Imaging
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel

## Key facts

- **NCT ID:** NCT04539808
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-27
- **Primary completion:** 2024-12-08
- **Final completion:** 2027-01-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539808, "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04539808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*